Loomis Sayles & Co. L P Sells 43,979 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Loomis Sayles & Co. L P cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 525,303 shares of the biopharmaceutical company’s stock after selling 43,979 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Alnylam Pharmaceuticals were worth $144,474,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Plato Investment Management Ltd grew its position in shares of Alnylam Pharmaceuticals by 2,666.3% in the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock valued at $674,000 after purchasing an additional 4,346 shares during the last quarter. Diversified Trust Co acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $1,210,000. Los Angeles Capital Management LLC increased its position in Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after buying an additional 135,829 shares during the period. Breakwater Capital Group acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $249,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $578,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.8 %

Shares of ALNY stock opened at $244.89 on Monday. The firm’s 50 day moving average price is $273.13 and its two-hundred day moving average price is $238.67. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. The firm’s revenue was down 33.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.15 EPS. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ALNY shares. Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Raymond James upped their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. lifted their target price on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.